Rev Esp Quimioter 2019; 32(2): 178-182

Bronchospasm and flushing after vaccination with 23 serotype pneumococcal polysaccharide in chronic patients

MARÍA FERNÁNDEZ-PRADA, ALBA MARTÍNEZ-TORRÓN, MARÍA JOSÉ CUERVO-LAGE, JESÚS RUIZ- SALAZAR, CARMEN MARTÍNEZ-ORTEGA, FEDERICO FERNÁNDEZ-NOVAL, ISMAEL HUERTA-GONZÁLEZ

Objectives. To describe the clinical-epidemiological characteristics of a series of suspected systemic adverse reactions registered with the 23 serotype pneumococcal polysaccharide vaccine (PNEUMOVAX23®). Calculate the cumulative incidence of the reaction and know if similar and/or compatible cases have been described in the scientific literature or in pharmacovigilance.
Methods. Observational and retrospective study realized between 01/12/2015 and 30/09/2017 in the Vaccines Unit of an autonomic reference hospital. We calculated the cumulative incidence of the adverse reaction for that vaccine. The common pharmacovigilance database (FEDRA) was consulted.
Results. Nine systemic adverse reactions were recorded (flushing + bronchospasm + SatO2<95%). The cumulative incidence was 1.036%. The outcome was recovered/resolved for everyone. No similar and/or compatible cases were found.
Conclusions. The reactions described do not appear in the PNEUMOVAX23® data sheet. Epidemiologically, no causal relationship can be established between the symptoms and the variables studied. This study could be the basis for more detailed research that could modify the vaccine data sheet.

Rev Esp Quimioter 2019; 32(2): 178-182 [Texto completo PDF]